v3.26.3
Shareholders' Equity
 9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
Shareholders' Equity Shareholders’ Equity
Share repurchase program. The Company did not repurchase shares of its common stock in open-market transactions under the share repurchase program during the nine months ended September 30, 2026. As of September 30, 2026, the Board of Directors has authorized the Company to repurchase up to an additional $1.1 billion of the Company’s common stock.
Dividends. Cash dividends declared and paid per common share for the three and nine months ended September 30, 2026 and 2025 were as follows: 
Three months ended September 30,Nine months ended September 30,
2026202520262025
Cash dividends declared and paid per common share$0.68 $0.67 $2.04 $2.01 
Net income (loss) per share. Basic net income (loss) per share was computed by dividing net income (loss) available to common shareholders by the weighted-average number of common shares outstanding during each period, including shares earned under the Deferred Compensation Plan for Directors (“Director Plan”), the ESOP and deferred stock units under the Amended and Restated 2024 Omnibus Incentive Plan (“Omnibus Plan”). Diluted net income (loss) per share was computed under the treasury stock method and was calculated to compute the dilutive effect of outstanding stock options and certain share-based awards issued under the Omnibus Plan. As a result of the Company’s net loss during the three and nine months ended September 30, 2025, outstanding stock options and certain share-based awards were not included in the computation of diluted net loss per share for such periods because the effect would have been anti-dilutive. Reconciliations of these amounts are as follows (in millions):
Three months ended September 30,Nine months ended September 30,
2026202520262025
Weighted average number of common shares outstanding 56.9 56.2 56.8 56.2 
Director Plan and deferred stock units 0.4 0.4 0.4 0.3 
ESOP 0.3 0.3 0.3 0.4 
Common shares outstanding-basic 57.6 56.9 57.5 56.9 
Dilutive effect of restricted stock units0.7 — 0.7 — 
Dilutive effect of stock option awards0.2 — 0.1 — 
Common and potential common shares outstanding-diluted 58.5 56.9 58.3 56.9 
During the three and nine months ended September 30, 2026, the number of options that were not included in the computation of diluted net income (loss) per share because the option exercise price was greater than the market price, and therefore the effect would have been anti-dilutive, was 2.9 million, compared to 2.9 million and 3.3 million, respectively, for the comparable periods in 2025. As a result of the Company’s net loss during the three and nine months ended September 30, 2025, an additional 0.6 million and 0.3 million, respectively, of outstanding stock options and certain share-based awards under the Omnibus Plan were not included in the computation of diluted net loss per share because the effect would have been anti-dilutive.
Accumulated other comprehensive loss. Changes in the accumulated other comprehensive loss balance were as follows (in millions):
Foreign Currency TranslationCash Flow Hedging DerivativesRetirement Plan ActivityAccumulated Other Comprehensive Loss
Balance as of December 31, 2025$(35.7)$1.3 $2.3 $(32.1)
Reclassification to the statement of income — (7.1)(0.3)(7.4)
Change in fair value (20.4)15.8 — (4.6)
Balance as of September 30, 2026$(56.1)$10.0 $2.0 $(44.1)